Literature DB >> 23119476

Squamous cell carcinoma of the maxillary sinus: A retrospective analysis of 36 cases.

D Passali1, B D Capua, A D Lauretis, E Tucci, R Petrioli, L Bellussi, G Franci.   

Abstract

36 patients with advanced squamous cell carcinomas of the maxillary sinuses formed the basis of this review. There were 16 T3 and 20 T4. Treatment consisted of radiotherapy alone in 21 cases and radiotherapy followed by systemic chemotherapy in 15 cases. The median survival for all analysed patients was 19 months and the 3-year and 5-year estimated survivals were 30% and 17%. The respective 3-and 5-year survival probabilities were 19% and 9% for patients treated with radiotherapy alone and 40% and 27% for patients treated with radiotherapy and chemotherapy (p= 0.01). Our findings seem to suggest that the addititon of systemic chemotherapy to radiotherapy may imporve overall survival in advanced squamous cell carcinomas of the maxillary sinuses.

Entities:  

Year:  1999        PMID: 23119476      PMCID: PMC3451488          DOI: 10.1007/BF02996837

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  17 in total

1.  Squamous cell carcinoma of the paranasal sinuses: the Cleveland Clinic experience 1977-1986.

Authors:  P Lavertu; J K Roberts; D H Kraus; H L Levine; B G Wood; S V Medendorp; H M Tucker
Journal:  Laryngoscope       Date:  1989-11       Impact factor: 3.325

2.  Preoperative versus postoperative radiation in the treatment of squamous carcinoma of the paranasal sinuses.

Authors:  R H Jesse
Journal:  Am J Surg       Date:  1965-10       Impact factor: 2.565

3.  Combined multimodality (surgery, radiotherapy, intra-arterial chemotherapy) treatment of advanced carcinoma of paranasal sinuses.

Authors:  M Shafir; E Raventos
Journal:  Recent Results Cancer Res       Date:  1983

4.  Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer.

Authors:  M H Amer; M Al-Sarraf; V K Vaitkevicius
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

5.  Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.

Authors:  J A Kish; A Weaver; J Jacobs; G Cummings; M Al-Sarraf
Journal:  Cancer       Date:  1984-05-01       Impact factor: 6.860

6.  Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.

Authors:  E E Vokes; R R Weichselbaum; R Mick; J M McEvilly; D J Haraf; W R Panje
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

7.  Treatment of advanced squamous carcinoma of the maxillary sinus by irradiation.

Authors:  J C Frich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-08       Impact factor: 7.038

8.  Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University.

Authors:  P LoRusso; E Tapazoglou; J A Kish; J F Ensley; G Cummings; J Kelly; M al-Sarraf
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

Review 9.  Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses.

Authors:  C S Muir; J Nectoux
Journal:  Clin Otolaryngol Allied Sci       Date:  1980-06

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  1 in total

Review 1.  Squamous cell carcinoma at maxillary sinus: clinicopathologic data in a single Brazilian institution with review of literature.

Authors:  Marcello Roter M Santos; João Paulo S Servato; Sérgio Vitorino Cardoso; Paulo Rogério de Faria; Ana Lúcia A Eisenberg; Fernando Luiz Dias; Adriano Mota Loyola
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.